



ImmunoCellular
Investor Relations Department
23622 Calabasas Road
Suite 300
Calabasas, CA 91302
United States

Visit IR website

AMEX: IMUC

Last Trade:	0.27
Trade Time:	10:49 AM ET March 21, 2018
Change:	0.01 (2.457%)
Day Range	0.26 - 0.28
52-Week Range	0.17 - 3.60
Volume	159,982

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- March 13, 2018*
[ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results](#)
- March 7, 2018*
[ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018](#)
- February 22, 2018*
[ImmunoCellular Therapeutics Announces Review of Strategic Alternatives](#)
- February 13, 2018*
[ImmunoCellular Therapeutics Announces Update on Financial Condition](#)
- December 13, 2017*
[ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program](#)

Financials [\[View all \]](#)

- March 14, 2018*
[Annual Report \(10-K\)](#)
- April 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- November 21, 2017*
[Quarterly Report \(10-Q\)](#)
- August 14, 2017*
[Quarterly Report \(10-Q\)](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)